357 related articles for article (PubMed ID: 33964370)
21. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.
Mohs A; Otto T; Schneider KM; Peltzer M; Boekschoten M; Holland CH; Hudert CA; Kalveram L; Wiegand S; Saez-Rodriguez J; Longerich T; Hengstler JG; Trautwein C
J Hepatol; 2021 Mar; 74(3):638-648. PubMed ID: 33342543
[TBL] [Abstract][Full Text] [Related]
22. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis.
Nishina H
Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740
[TBL] [Abstract][Full Text] [Related]
23. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
24. Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation-driven hepatocarcinogenesis.
Liang B; Wang H; Qiao Y; Wang X; Qian M; Song X; Zhou Y; Zhang Y; Shang R; Che L; Chen Y; Huang Z; Wu H; Monga SP; Zeng Y; Calvisi DF; Chen X; Chen X
Hepatology; 2023 Jun; 77(6):1929-1942. PubMed ID: 35921500
[TBL] [Abstract][Full Text] [Related]
25. A critical role for NF2 and the Hippo pathway in branching morphogenesis.
Reginensi A; Enderle L; Gregorieff A; Johnson RL; Wrana JL; McNeill H
Nat Commun; 2016 Aug; 7():12309. PubMed ID: 27480037
[TBL] [Abstract][Full Text] [Related]
26. Proliferation of hepatic stellate cells, mediated by YAP and TAZ, contributes to liver repair and regeneration after liver ischemia-reperfusion injury.
Konishi T; Schuster RM; Lentsch AB
Am J Physiol Gastrointest Liver Physiol; 2018 Apr; 314(4):G471-G482. PubMed ID: 29351389
[TBL] [Abstract][Full Text] [Related]
27. Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice.
Moya IM; Castaldo SA; Van den Mooter L; Soheily S; Sansores-Garcia L; Jacobs J; Mannaerts I; Xie J; Verboven E; Hillen H; Algueró-Nadal A; Karaman R; Van Haele M; Kowalczyk W; De Waegeneer M; Verhulst S; Karras P; van Huffel L; Zender L; Marine JC; Roskams T; Johnson R; Aerts S; van Grunsven LA; Halder G
Science; 2019 Nov; 366(6468):1029-1034. PubMed ID: 31754005
[TBL] [Abstract][Full Text] [Related]
28. Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.
Serinagaoglu Y; Paré J; Giovannini M; Cao X
Dev Biol; 2015 Feb; 398(1):97-109. PubMed ID: 25433207
[TBL] [Abstract][Full Text] [Related]
29. Deregulation of the Hippo pathway in mouse mammary stem cells promotes mammary tumorigenesis.
Li H; Gumbiner BM
Mamm Genome; 2016 Dec; 27(11-12):556-564. PubMed ID: 27601049
[TBL] [Abstract][Full Text] [Related]
30. Merlin/NF2-Lin28B-let-7 Is a Tumor-Suppressive Pathway that Is Cell-Density Dependent and Hippo Independent.
Hikasa H; Sekido Y; Suzuki A
Cell Rep; 2016 Mar; 14(12):2950-61. PubMed ID: 26997273
[TBL] [Abstract][Full Text] [Related]
31. TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
Wang X; Zeldin S; Shi H; Zhu C; Saito Y; Corey KE; Osganian SA; Remotti HE; Verna EC; Pajvani UB; Schwabe RF; Tabas I
J Hepatol; 2022 Apr; 76(4):910-920. PubMed ID: 34902531
[TBL] [Abstract][Full Text] [Related]
32. Hippo signaling pathway in companion animal diseases, an under investigated signaling cascade.
Budel SJ; Penning MM; Penning LC
Vet Q; 2021 Dec; 41(1):172-180. PubMed ID: 33945400
[TBL] [Abstract][Full Text] [Related]
33. Hepatic Hippo signaling inhibits development of hepatocellular carcinoma.
Liu Y; Wang X; Yang Y
Clin Mol Hepatol; 2020 Oct; 26(4):742-750. PubMed ID: 32981290
[TBL] [Abstract][Full Text] [Related]
34. Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer.
Jeong SH; Kim HB; Kim MC; Lee JM; Lee JH; Kim JH; Kim JW; Park WY; Kim SY; Kim JB; Kim H; Kim JM; Choi HS; Lim DS
J Clin Invest; 2018 Mar; 128(3):1010-1025. PubMed ID: 29400692
[TBL] [Abstract][Full Text] [Related]
35. Molecular alterations of the NF2 gene in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Zhang N; Zhao Z; Long J; Li H; Zhang B; Chen G; Li X; Lv T; Zhang W; Ou X; Xu A; Huang J
Oncol Rep; 2017 Dec; 38(6):3650-3658. PubMed ID: 29130106
[TBL] [Abstract][Full Text] [Related]
36. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
[TBL] [Abstract][Full Text] [Related]
37. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals.
Zhang N; Bai H; David KK; Dong J; Zheng Y; Cai J; Giovannini M; Liu P; Anders RA; Pan D
Dev Cell; 2010 Jul; 19(1):27-38. PubMed ID: 20643348
[TBL] [Abstract][Full Text] [Related]
38. Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ.
Yi J; Lu L; Yanger K; Wang W; Sohn BH; Stanger BZ; Zhang M; Martin JF; Ajani JA; Chen J; Lee JS; Song S; Johnson RL
Hepatology; 2016 Nov; 64(5):1757-1772. PubMed ID: 27531557
[TBL] [Abstract][Full Text] [Related]
39. The Hippo pathway member Nf2 is required for inner cell mass specification.
Cockburn K; Biechele S; Garner J; Rossant J
Curr Biol; 2013 Jul; 23(13):1195-201. PubMed ID: 23791728
[TBL] [Abstract][Full Text] [Related]
40. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.
Striedinger K; VandenBerg SR; Baia GS; McDermott MW; Gutmann DH; Lal A
Neoplasia; 2008 Nov; 10(11):1204-12. PubMed ID: 18953429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
